Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 234 USD 1.41% Market Closed
Market Cap: $563.8B

Relative Value

The Relative Value of one JNJ stock under the Base Case scenario is 171.49 USD. Compared to the current market price of 234 USD, Johnson & Johnson is Overvalued by 27%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

JNJ Relative Value
Base Case
171.49 USD
Overvaluation 27%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

JNJ Competitors Multiples
Johnson & Johnson Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Johnson & Johnson
NYSE:JNJ
563B USD 6 21 14.6 17.9
US
Eli Lilly and Co
NYSE:LLY
948.8B USD 16 51.5 34.6 37.1
CH
Roche Holding AG
SIX:ROG
282B CHF 4.6 30 12.7 14.8
UK
AstraZeneca PLC
LSE:AZN
214.9B GBP 5.1 31.7 15.1 22.1
US
Merck & Co Inc
NYSE:MRK
288.1B USD 4.5 15.1 10.7 12.7
CH
Novartis AG
SIX:NOVN
225.6B CHF 5.2 20.2 12.7 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.9 11 12.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
146.4B USD 2.3 14.9 7.6 10.3
FR
Sanofi SA
PAR:SAN
98B EUR 1.7 8.2 7.7 7.7
US
Bristol-Myers Squibb Co
NYSE:BMY
114.1B USD 2.4 18.9 6.8 8.8
P/E Multiple
Earnings Growth PEG
US
Johnson & Johnson
NYSE:JNJ
Average P/E: 22.7
21
6%
3.5
US
Eli Lilly and Co
NYSE:LLY
51.5
54%
1
CH
Roche Holding AG
SIX:ROG
30
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.7
38%
0.8
US
Merck & Co Inc
NYSE:MRK
15.1
14%
1.1
CH
Novartis AG
SIX:NOVN
20.2
17%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
15.9
2%
8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
FR
Sanofi SA
PAR:SAN
8.2
1%
8.2
US
Bristol-Myers Squibb Co
NYSE:BMY
18.9
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Johnson & Johnson
NYSE:JNJ
Average EV/EBITDA: 42.4
14.6
2%
7.3
US
Eli Lilly and Co
NYSE:LLY
34.6
34%
1
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
15.1
10%
1.5
US
Merck & Co Inc
NYSE:MRK
10.7
6%
1.8
CH
Novartis AG
SIX:NOVN
12.7
6%
2.1
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
US
Bristol-Myers Squibb Co
NYSE:BMY
6.8
-9%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Johnson & Johnson
NYSE:JNJ
Average EV/EBIT: 90.6
17.9
6%
3
US
Eli Lilly and Co
NYSE:LLY
37.1
37%
1
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
22.1
23%
1
US
Merck & Co Inc
NYSE:MRK
12.7
8%
1.6
CH
Novartis AG
SIX:NOVN
16.4
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
10%
0.9